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Integrative analysis 
of multi‑platform reverse‑phase 
protein array data 
for the pharmacodynamic 
assessment of response to targeted 
therapies
Adam Byron 1*, Stephan Bernhardt 2,5, Bérèngere Ouine3, Aurélie Cartier3,6, 
Kenneth G. Macleod1, Neil O. Carragher 1, Vonick Sibut4,7, Ulrike Korf2, Bryan Serrels 1,8 & 
Leanne de Koning 3*
Reverse‑phase protein array (RPPA) technology uses panels of high‑specificity antibodies to measure 
proteins and protein post‑translational modifications in cells and tissues. The approach offers 
sensitive and precise quantification of large numbers of samples and has thus found applications in 
the analysis of clinical and pre‑clinical samples. For effective integration into drug development and 
clinical practice, robust assays with consistent results are essential. Leveraging a collaborative RPPA 
model, we set out to assess the variability between three different RPPA platforms using distinct 
instrument set‑ups and workflows. Employing multiple RPPA‑based approaches operated across 
distinct laboratories, we characterised a range of human breast cancer cells and their protein‑level 
responses to two clinically relevant cancer drugs. We integrated multi‑platform RPPA data and used 
unsupervised learning to identify protein expression and phosphorylation signatures that were not 
dependent on RPPA platform and analysis workflow. Our findings indicate that proteomic analyses 
of cancer cell lines using different RPPA platforms can identify concordant profiles of response to 
pharmacological inhibition, including when using different antibodies to measure the same target 
antigens. These results highlight the robustness and the reproducibility of RPPA technology and its 
capacity to identify protein markers of disease or response to therapy.
In the era of personalised medicine and targeted cancer therapies, identifying those patients that will benefit 
from existing and new therapies is paramount. Genetics is already being used to assist clinical decision-making 
in specific  cases1, but additional levels of biological information are required to better understand disease and 
more accurately predict phenotype from  genotype2. A crucial source of information in this context is the pro-
teome and, notably, the activation status of dynamic cell signalling pathways through post-translational protein 
modifications. Indeed, genomic mutations are not always associated with activated signalling pathways and, 
conversely, pathway activation can occur in the absence of mutations, as exemplified by PIK3CA3 and human 
epidermal growth factor receptor 2 (Her2, also known as ErbB2)  signalling4 in breast cancer.
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Several technologies exist for protein biomarker discovery and  validation5–7, among which reverse-phase 
protein array (RPPA) is a technology of choice for its unequalled sample throughput. The RPPA technology uses 
panels of monospecific affinity reagents (usually validated, high-quality antibodies) to quantify, with high preci-
sion and sensitivity, the abundance of specific proteins and their post-translationally modified forms in biological 
 specimens8,9. Protein samples derived from cells or tissues are immobilised on a solid substrate, deposited as 
small spots on multiple arrays, and each array is probed with a single, epitope-specific antibody. This enables 
simultaneous quantification of multiple proteins and post-translational modifications in hundreds of samples, 
a multiplex capability not available in any other current proteomic technology. The capacity to analyse large 
sample numbers enables analysis of multiple sample conditions, such as drug treatments, dose responses and 
time courses, resulting in data series that can support systems biology and drug discovery  pipelines10,11. The 
high sensitivity (in the picomole–femtomole range) and good reproducibility of RPPA  technology8,12–16 have 
motivated its application to a wide range of sample types, including cell lines, preclinical (e.g. xenograft) models 
and patient-derived material. Indeed, the microscale printing of very small amounts of samples is of particular 
benefit for analysis of limited clinical or preclinical material, and RPPA has become a powerful addition to the 
biomedical analytical toolbox for the investigation of disease mechanisms, diagnostics and prognostics, notably 
in  cancer17–26.
The RPPA workflow is composed of several distinct steps, which can each be adapted to the needs of the labo-
ratory or the study. RPPAs thus offer a highly flexible, modular proteomic technology, enabling numerous pos-
sible technical set-ups and protocols. As most laboratories using RPPA technology have developed a customised 
set-up, there are essentially as many workflows as there are RPPA platforms. Differences between platforms are 
diverse and can include the type of printer used to create the arrays, sample spotting conditions, slide substrate 
chemistry, primary and secondary antibodies used for immunostaining and slide scanner  optics27. Moreover, no 
standard tools exist to quantify, normalise and quality control RPPA data. Several RPPA data processing methods 
have been  developed16,28–40, but these are often designed for specific technical set-ups, requiring, for example, 
particular array layouts or raw data formats. To our knowledge, no extensive cross-platform validation has 
been reported for RPPA technology. There is, therefore, a need to assess and understand the impact of variation 
between RPPA data derived from different platforms across international research centres.
As RPPA workflows are being developed for use in clinical settings, for which robust assays are  paramount41,42, 
there is a growing need for the evaluation of the reproducibility of RPPA platform outputs. Herein, we use col-
laborative RPPA-based proteomics, employing distinct RPPA workflows at multiple research sites in different 
countries, to characterise a range of human breast cancer cell lines and their biochemical responses to two clini-
cally relevant cancer drugs. We combine data derived from different RPPA platforms to assess inter-platform 
variation and use integrative analysis to identify platform-independent protein markers of response to drug 
treatment. Such cross-platform validation may thus have utility in multi-centre evaluation of robust protein 
markers of disease and therapeutic response.
Results
Multi‑platform RPPA analysis of breast cancer cell lines. To assess the reproducibility of RPPA 
technology across multiple laboratories, we developed an international multi-platform approach that integrated 
RPPA data derived from three research sites across Europe (Paris, France; Heidelberg, Germany; Edinburgh, 
United Kingdom). We selected for this study six breast cancer cell lines, encompassing different breast cancer 
molecular subtypes and presenting distinct drug sensitivities (Supplementary Table S1). The cells were cultured 
in the absence or presence of two kinase inhibitors for 20 min or 24 h and lysed in biological triplicate. In total, 
we generated 108 snap-frozen lysates, which were shipped to the three research sites (Fig. 1a). Samples were 
analysed at each site using the respective in-house RPPA platforms, the set-up of which differed at many stages 
of the RPPA analysis workflow, including slide type, the number of technical replicates and dilutions per sample, 
read-out dye, scanner, image analysis software and normalisation procedure (Supplementary Table S2), enabling 
the capture of variation between RPPA platforms operated in different laboratories. Microarrayed samples were 
probed with panels of validated antibodies in routine use on the three RPPA platforms. To enable dataset com-
parison, all antibodies were assigned unique antibody identifiers, and only data derived from antibodies target-
ing the same protein(s) or phosphorylated residue(s) (including different antibodies from different suppliers) 
acquired on all three RPPA platforms were used for further analysis (Supplementary Table S3). This experimen-
tal design thus enabled the assessment of inter-platform concordance.
First, RPPA data of the six breast cancer cell lines cultured under control conditions were analysed using 
the respective in-house data analysis procedures of the three research sites. Analysis of these control samples 
generated in biological triplicate with antibodies used in the multi-platform RPPA analysis resulted in 522, 558 
and 486 antibody readings (processed signal intensities) for the Paris, Heidelberg and Edinburgh platforms, 
respectively. Normalised RPPA data derived from each platform were then clustered antibody-wise to identify 
similarities between validated antibodies (Supplementary Table S4). For each RPPA platform, clusters containing 
antibodies targeting the same protein or phosphoprotein were identified, indicating that normalised intensity 
profiles across cell types correlated for subsets of different antibodies (Fig. 1b–d, Supplementary Fig. S1). Most 
distinct antibodies targeting the same antigen, such as phosphorylated Erk1/2, clustered together in each RPPA 
dataset, indicating consistent results for the same antigen (Fig. 1e–g, Supplementary Fig. S1). In addition, anti-
bodies targeting different phosphorylated residues on the same protein or antibodies targeting phosphorylated 
and corresponding total proteins, such as for S6 ribosomal protein or mTOR, generally clustered together in each 
RPPA dataset, although the degree of correlation varied between RPPA platforms and distance metrics (Fig. 1b–d, 
Supplementary Fig. S1). These data suggest that many of the antibodies routinely used for RPPA analysis at the 
three research sites in this study give comparable results relative to the rest of each dataset.
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Figure 1.  Multi-platform RPPA analysis of breast cancer cell lines. (a) Schematic illustration of the multi-
platform RPPA workflow. Images created using Illustrator. (b–d) Hierarchical cluster analysis of RPPA data of 
six breast cancer cell lines cultured under control conditions derived from three RPPA platforms. RPPA data 
derived from the Paris (b), Heidelberg (c) and Edinburgh (d) platforms were clustered on the basis of antibody-
wise dissimilarity (Spearman rank correlation coefficient-based distance). Clustering was performed separately 
for each platform, and sample order was maintained for each cluster analysis. Annotation bars indicate cell type, 
cell type receptor status and RPPA platform. Arrowheads indicate different phosphorylated Erk1/2 antibodies. 
(e–g) RPPA data for phosphorylated Erk1/2 (pThr202/Thr185, pTyr204/Tyr187) derived from the Paris (e), 
Heidelberg (f) and Edinburgh (g) RPPA platforms. All three platforms used the same two antibodies that 
recognise phosphorylated Erk1/2 (dark bars, antibody identifier Erk1/2_pThr202/Thr185,pTyr204/Tyr187_a; 
light bars, antibody identifier Erk1/2_pThr202/Thr185,pTyr204/Tyr187_b). Annotation bars (x-axis) indicate 
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Integrative analysis of multi‑platform RPPA data. To assess the comparability of RPPA data origi-
nating from multiple platforms, we integrated normalised RPPA data for control samples derived from each 
platform (1566 antibody readings) and analysed the integrated dataset using unsupervised learning. For dataset 
integration, antigens targeted by each antibody were classified, capturing antibody recognition of related protein 
isoforms or family members where applicable (e.g. antibodies recognising Erk1 and Erk1/2 were linked and 
assigned the same antibody antigen class, Erk1/2). Each data point was linked to the RPPA platform from which 
it was derived to enable downstream data analysis. We reduced the dimensionality of the integrated multi-plat-
form RPPA dataset using principal component analysis. This unsupervised analysis of the six breast cancer cell 
lines revealed separation in feature space for several of the cell types, indicating cell type-specific expression of 
the proteins and phosphoproteins measured (Fig. 2a). Next, two-dimensional hierarchical cluster analysis of the 
integrated dataset, using multiple distinct distance functions to quantify dissimilarity between data points in the 
feature space, partitioned samples by breast cancer cell line, elucidating discriminatory profiles of protein and 
phosphoprotein expression for each cell type (Fig. 2b, Supplementary Fig. S2). Moreover, unsupervised cluster 
analysis identified correlated subsets of antibodies targeting the same antigens. The data driving these antibody 
clusters were generally derived from multiple RPPA platforms and, where available, using different antibodies 
(Fig. 2b, Supplementary Table S5), suggesting that the profiles of protein and phosphoprotein expression were 
comparable between RPPA platform set-ups.
To interrogate the similarity between antigen expression profiles for distinct antibodies used on different 
RPPA platforms, we devised a data-driven representation of antibody similarity, which we termed a clustered 
antibody antigen map. Antibodies used at each RPPA platform (clustered as for Fig. 2b) were annotated with 
their respective antigens (classified as described in “Methods”). With clustered antibodies as columns, antigen 
annotations were expanded into rows of a matrix. The resulting matrix was populated with unique antibody 
identifiers to distinguish different antibodies, from which a heatmap of clustered antibody–antigen space was 
generated. Thus, the antibody antigen map provides detailed annotation of cluster analysis of multi-platform 
RPPA data. This enables identification of clustered antibodies that recognise antigens with similar expression 
profiles across the integrated dataset (Fig. 2b,c, Supplementary Fig. S2).
The antibody antigen map revealed that the expression of many of the antigens tested (71%) clustered with 
expression of the same antigen determined by at least one other RPPA platform (Fig. 2c,d). In addition, the 
expression of several of the antigens for which distinct antibodies were used (61%) clustered with the same anti-
gen detected by a different antibody (Fig. 2c,d). Together, these results indicate that RPPA analyses performed 
at different research sites using distinct set-ups can identify concordant sets of distinct antibodies that target the 
same antigens. This implies that different high-quality, validated antibodies can be used to generate consistent 
results from the same samples using different RPPA platforms.
Consistency of multi‑platform RPPA analysis of drug‑treated breast cancer cell lines. To ana-
lyse the robustness of RPPA technology using a more relevant ‘intervention’ dataset (i.e. including treatment con-
ditions), we extended the integrative analysis to include multi-platform RPPA data of the six breast cancer cell 
lines treated with two clinically relevant drugs, lapatinib (Tykerb, Tyverb) and selumetinib (AZD6244, ARRY-
142886). Lapatinib is a reversible ATP-mimetic tyrosine kinase inhibitor of epidermal growth factor receptor 
(EGFR, also known as ErbB1) and  Her243; selumetinib is a selective ATP-independent allosteric inhibitor of 
mitogen-activated protein kinase kinase (MAPKK, also known as MEK)44. To capture the signalling dynamics of 
the proteins under investigation, cells were treated with either drug or with DMSO (vehicle control) for 20 min 
and 24 h (Fig. 3a).
First, to examine the consistency of results generated by the antibodies used in the multi-platform RPPA 
analysis, we calculated correlations between all-sample RPPA data derived from all antibodies tested, which 
consisted of 9,396 antibody readings. This analysis showed that RPPA data derived from antibodies recognising 
the same antigen class (i.e. ‘like’ antigens) were generally well correlated (median Spearman rank correlation 
coefficient, rs = 0.70) (Fig. 3b). In contrast, data derived from all antibodies—regardless of target—were generally 
poorly correlated (rs = 0.22), as expected (Fig. 3b), implying that RPPA-based quantification of like target antigens 
is in substantially better agreement than quantification of random antigens in the dataset. Notably, RPPA data 
for antigens recognised by the same antibody were correlated to a similar level to those recognised by differ-
ent antibodies (Fig. 3c), indicating that distinct, validated antibodies generate consistent results from the same 
samples. In addition, correlations between normalised RPPA data derived from all antibodies were lower than 
those between corresponding raw RPPA data, resulting in a better separation of correlation distributions for like 
antigens and for all antibodies (Supplementary Fig. S3). This suggests that normalisation of RPPA data better 
differentiates concordant data (derived from antibodies recognising the same antigen class) from less-concordant 
data (derived from all antibodies regardless of target).
To assess the reproducibility of RPPA results across different RPPA platforms, we compared correlation 
distributions for like antigens for each pair-wise combination of platforms. Each platform comparison showed 
a similar correlation distribution for antigens recognised by the same antibodies (Fig. 3d) and a similar correla-
tion distribution for antigens recognised by different antibodies (Fig. 3e), although different antibodies used at 
the Paris and Edinburgh platforms were less well correlated. Strong positive correlations between platforms did 
not appear to be restricted to high-intensity RPPA data (Supplementary Fig. S3), suggesting that the observed 
correlation distributions were not driven solely by samples with high levels of antigen expression. Importantly, 
antigens detected by different antibodies used at different RPPA platforms were, in general, almost as well cor-
related as those used at the same RPPA platform (Fig. 3f). These data show that RPPA analyses of the same 
samples at different platforms using distinct workflows yield consistent results, including when several different 
antibodies are used to recognise the same antigen (protein or phosphoprotein) of interest.
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Integrative multi‑platform RPPA analysis of drug‑treated breast cancer cell lines. We hypoth-
esised that the observed consistency of multi-platform RPPA data would allow robust detection of potential 
markers of cellular response to signalling pathway inhibition. To confirm overall changes in RPPA data upon 
drug treatment of breast cancer cells, we reduced the dimensionality of the integrated dataset using principal 
component analysis. Unsupervised analysis of all cell lines identified shifts in feature space away from control 
conditions for some drug-treated cells, suggesting cell type-specific differential regulation of proteins and phos-
phoproteins (Supplementary Fig. S4). For example, the Her2-amplified SKBR3 cell line is highly sensitive to 
 lapatinib45,46, and treatment with lapatinib induced substantial changes in phosphoprotein abundance, including 
Figure 2.  Integrative analysis of multi-platform RPPA data. (a) Principal component analysis of integrated 
multi-platform RPPA data of six breast cancer cell lines cultured under control conditions. (b) Integrated multi-
platform RPPA data were clustered on the basis of antibody-wise and sample-wise dissimilarities (Spearman 
rank correlation coefficient-based distance). Annotation bars indicate cell type, cell type receptor status and 
RPPA platform. (c) Clustered antibody antigen map for all antibodies used in the integrative analysis. The map 
is aligned with the hierarchical clustering results in (b) [grey dashed line above the left-most antibody indicates 
alignment of the first antibody (column) end-node]. Distinct antibodies that target the same antigen class 
(unique antibody identifiers) are indicated by different shades of purple. Antibody antigen classes are ordered 
alphabetically for clarity. (d) Exemplar of clustered antibodies that recognise Her2, indicated by grey dashed 
box in (b) and (c). Antibodies used by all three RPPA platforms clustered in antibody–antibody antigen space. 
Spearman rank correlation coefficient of the cluster column node is shown in grey. All three platforms used 
different antibodies that recognise Her2 (antibody identifiers for Paris, Her2_b; Heidelberg, Her2_d; Edinburgh, 
Her2_a). For further details, see Supplementary Fig. S2 and Supplementary Table S5.
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that of phosphorylated Her2 and EGFR and downstream signalling molecules Akt and Erk1/2 (Fig. 4a,b, Supple-
mentary Fig. S4). In contrast, dimensionality-reduced RPPA data for MCF7 cells, which do not overexpress Her2 
or EGFR, did not display a large shift in feature space away from control conditions, in keeping with the lack 
of response to lapatinib treatment of MCF7 cells (Supplementary Fig. S4). For cells treated with selumetinib, a 
strong reduction in phosphorylated Erk1/2—which is activated upon phosphorylation by  MEK47—was observed 
in MEK inhibitor-sensitive MDA-MB-231 cells analysed at all RPPA platforms (Fig. 4a,b), whereas SKBR3 cells, 
which are not as sensitive to selumetinib, displayed a minimal shift in feature space for selumetinib-treated 
samples (Fig. 4a). In some cell lines, upregulation of phosphorylated MEK1/2 was observed upon selumetinib 
treatment, particularly after treatment for 24 h, representing the likely effects of reduced negative feedback on 
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Figure 3.  Correlations of RPPA data used for integrative analysis of drug-treated breast cancer cell lines. (a) 
Schematic illustration of the drug treatment experiment. Samples were processed as part of the same workflow 
shown in Fig. 1. Images created using Illustrator. (b) Correlations of RPPA data derived from antibodies 
recognising the same antigen class (like antigens) were compared to those derived from all antibodies used in 
the integrated multi-platform RPPA dataset. (c) For like antigens, correlations of RPPA data derived from the 
same antibodies were compared to those derived from different antibodies. (d,e) Correlations between RPPA 
data generated at the different RPPA platforms were compared for data derived from the same antibodies (d) 
and different antibodies recognising like antigens (e). (f) Correlations of RPPA data derived from different 
antibodies recognising like antigens generated on the same RPPA platform were compared to those generated 
on different RPPA platforms. For (b–f), kernel density estimates of Spearman rank correlation coefficients 
for every pair-wise combination of unique antibody identifiers were computed. Spearman rank correlation 
coefficient data points for each set of comparisons are indicated by rug plots. For each set of comparisons, 
the median Spearman rank correlation coefficient (rs) is shown (dashed lines). NS not significant. For further 
details, see Supplementary Fig. S3.
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the upstream MAPK pathway as a result of transiently inhibited Erk1/2 upon MEK  inhibition48,49. In general, 
for drug-sensitive cell lines, shifts in feature space were more pronounced for cells treated for 24 h as compared 
to 20 min, implying that the modulation of signalling pathways was enhanced when cells were challenged with 
drugs for longer, enabling modelling of the dynamic signalling landscape (Supplementary Fig. S4). Furthermore, 
in drug-resistant cell lines, we observed the emergence of potential resistance mechanisms, such as the activation 
of phosphorylated EGFR, Her2 and Akt in SKBR3 cells treated with selumetinib (Supplementary Fig. S4). These 
analyses show that the RPPA data represent expected changes in breast cancer cell responses to the pharmaco-
logical inhibitors tested, capturing relevant signalling dynamics, and serve as a suitable platform for the integra-
tive multi-platform RPPA analysis of drug-treated cells.
We next analysed the integrated RPPA dataset of drug-treated cell lines using unsupervised cluster analysis. 
Two-dimensional hierarchical clustering partitioned samples by breast cancer cell line, which were further par-
titioned by treatment condition (for respective drug-sensitive cells), with replicate samples clustering together, 
indicating robust data-driven grouping of the dataset (Fig. 4c, Supplementary Fig. S5, Supplementary Table S6). 
Clustered antibody antigen mapping, driven by this unsupervised dataset partitioning, identified clusters of anti-
bodies targeting the same antigen (Fig. 4d, Supplementary Fig. S5). As for the analysis of the cells cultured under 
control conditions (Fig. 2, Supplementary Fig. S2), expression of many of the antigens tested (75%) clustered 
with expression of the same antigen determined by at least one other RPPA platform (Fig. 4d). Furthermore, 
the expression of several of the antigens for which distinct antibodies were used (56%) clustered with the same 
antigen detected by a different antibody (Fig. 4d). Together, these results indicate that integrative RPPA analysis 
of drug-treated cells can identify concordant profiles of response to pharmacological inhibition using distinct 
antibodies and different RPPA platforms. This suggests that the robustness of RPPA technology is suitable for 
the characterisation of pathway signalling networks across international laboratories.
Discussion
With RPPA technology poised for adoption into routine clinical laboratory assays, there is a need to assess 
reproducibility and variation between RPPA data derived from different platforms. Herein, we employed a 
collaborative RPPA-based proteomics approach to evaluate the consistency of results obtained from the same 
samples using different RPPA workflows. We combined the RPPA data derived from multiple research sites to 
assess inter-platform variation and found that different RPPA platforms using distinct set-ups yield remarkably 
consistent results, including when several different antibodies are used to recognise the same antigen (protein 
or phosphoprotein) of interest. Indeed, antigens detected by different antibodies used at different RPPA plat-
forms were, in general, almost as well correlated as those used at the same RPPA platform. These observations 
strongly suggest that the different instrumental set-ups and analytical workflows used at these representative 
RPPA platforms do not preclude the generation of comparable and reproducible data when using high-quality, 
validated antibodies.
Using different workflows, the layout of samples spotted on arrays differed among the three RPPA platforms, 
which prevented application of the same automated data normalisation method. Each research site therefore 
applied their own in-house data normalisation procedure tailored for the respective RPPA platform. All plat-
forms normalised signal intensities for total amounts of printed protein, but the way they accounted for sample 
dilutions differed. The Paris platform applied non-parametric curve fitting to the serial dilutions of each sam-
ple, the Heidelberg platform fitted curves for control samples only and reported experimental samples to these 
curves and the Edinburgh platform computed a linear fit of the serially diluted samples. Despite these different 
approaches, we show that normalised data improves the distinction between concordant data (derived from 
antibodies recognising the same antigen class) and non-concordant data (derived from all antibodies regardless 
of target), as compared to raw data. Future efforts to develop normalisation pipelines that are compatible with 
multiple array layouts may further improve data reproducibility among platforms and expand opportunities for 
cross-platform validation of RPPA technology. Such cross-platform validation may have utility in the appraisal of 
robust markers of disease and therapeutic response and their application as prognostic or predictive biomarkers.
There is an outstanding need for the development of robust markers of response and resistance to targeted 
cancer  therapy5–7. Proteomic and phosphoproteomic datasets are well placed to complement genetics-based 
biomarker strategies by providing additional information on activation states of dynamic pathway signalling. 
However, the application of proteomic technologies presents a number of challenges, including consistent high-
quality sample preparation, sensitive detection of low-abundance proteins and post-translational modifications, 
high sample throughput at reasonable cost and rapid turnaround time necessary for clinical application or drug 
discovery and development pipelines. The development of RPPA workflows attempts to address many of these 
challenges, yet the reproducibility of RPPA data generation and analysis across distinct RPPA platforms and 
research centres has not been extensively evaluated. We used an integrative RPPA approach to characterise a 
range of human breast cancer cell lines and their biochemical responses to two clinically relevant cancer drugs. 
The cell lines were chosen to represent different molecular subtypes of breast cancer, each of which having a dif-
ferent prognosis and treatment  response50. The sensitivity of these cell lines towards lapatinib and selumetinib 
and the expected changes in major signalling pathways are  known51–53 and thus served as benchmarks in this 
study. We demonstrated that RPPA technology can identify expected protein markers for response to treatment 
and resistance in a robust and platform-independent manner. Although we analysed cell lines herein to enable 
benchmarking, RPPA is routinely applied to clinical samples, including small biopsies, on the platforms used in 
this study. In such cases, the amount of lysis buffer is adapted to the amount and the cellularity of the tissue in 
order to obtain sufficiently concentrated samples. We therefore expect that RPPA can robustly assess response to 
treatment and resistance independently of the analysed samples. Understanding how resistance can be predicted 
and prevented is a major therapeutic challenge, and the use of proteomic approaches such as RPPA will, by 
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defining the functional state of cells and tissues, enable the validation and assessment of resistance mechanisms 
in clinical  samples5,54.
High attrition rates in clinical drug development present significant challenges to drug developers, with only 
one in eight oncology drugs that enter clinical development in phase 1 achieving US Food and Drug Administra-
tion approval, and a 1-in-15 success rate when these candidate drugs are under evaluation in secondary oncology 
 indications55. The development of robust biomarkers is thus becoming an essential component of new clinical 
trial designs to guide patient selection, optimise dosing schedules and minimise ineffective or over-treatment. For 
many complex diseases, biomarkers at the genetic, proteomic, metabolomic and phenotypic levels are required 
to characterise individual patient disease and response to therapy sufficiently. Integration of multiple biomarker 
modalities with emerging computational and statistical approaches represents the future direction of personal-
ised medicine strategies. However, the successful implementation of personalised medicine is dependent upon 
the validation and reproducibility of biomarker tests performed across distinct research centres and national 
boundaries.
Our data show that RPPA analyses of drug-treated breast cancer cells using distinct antibodies and different 
RPPA platforms can identify robust profiles of protein markers reporting signalling pathway responses to phar-
macological inhibition. This suggests that the consistency of RPPA-based assays will enable the validation and 
assessment of treatment response and resistance mechanisms in clinical samples across international laboratories. 
These data provide, to our knowledge, the first extensive cross-platform validation of RPPA technology, which 
paves the way for further investigation and improvement of technology robustness.
Methods
Cell lines and cell lysis. MCF7, MDA-MB-231, MDA-MB-468, MDA-MB-453, HCC1954 and SKBR3 
breast cancer cells were purchased from American Type Culture Collection and grown according to supplied 
instructions (Supplementary Table S1). For the preparation of cell lysates, cells were washed twice with ice-cold 
phosphate-buffered saline (PBS). Laemmli buffer [50 mM Tris–HCl (pH 6.8), 2% sodium dodecyl sulfate, 5% 
glycerol, 2 mM DTT, 2.5 mM EDTA, 2.5 mM EGTA, supplemented with 4 mM sodium orthovanadate, 20 mM 
sodium fluoride, Halt phosphatase inhibitor cocktail (Perbio) and cOmplete protease inhibitor cocktail (Roche)] 
was incubated at 100 °C for 5 min and applied directly to cells. Samples were immediately incubated at 100 °C 
for 10 min. Lysates were passed through a 25-gauge needle five times and clarified by centrifugation (18,000×g, 
10 min, room temperature). Clarified lysates were aliquoted and snap-frozen in liquid nitrogen prior to ship-
ment to the various research sites. Protein concentration was determined using a reducing agent-compatible 
BCA kit (Pierce).
Pharmacological inhibitor treatment. Lapatinib and selumetinib (Selleck Chemicals) were prepared as 
10 mM stock solutions in DMSO. Cells were treated with 1 µM lapatinib, 1 µM selumetinib or DMSO in growth 
medium for 20 min or 24 h. Control cells were treated with DMSO in growth medium for 20 min.
RPPA analysis. Samples were analysed at each research site using the respective in-house RPPA platforms 
as summarised in Supplementary Table S2. For the Paris and Edinburgh platforms, all biological triplicate lysates 
were serially diluted to produce a dilution series comprising four serial twofold dilutions of each sample. For 
the Heidelberg platform, biological triplicate DMSO-treated control lysates were serially diluted to produce a 
control dilution series comprising six serial twofold dilutions of each control sample to enable representative 
dilution series intercept correction using RPPanalyzer as described  previously56. We confirmed that > 99% of 
data points derived from undiluted samples at the Heidelberg platform were within the dynamic range of the 
representative dilution series (Supplementary Fig. S5). Samples were spotted onto Grace Bio-Labs ONCYTE 
nitrocellulose-coated slides (Sigma-Aldrich) in technical duplicate or triplicate under conditions of constant 
70% humidity using an Aushon 2470 arrayer (Aushon Biosystems). Slides were hydrated in deionised water and 
blocked with blocking buffer (Supplementary Table S2). Slides were washed with Tris-buffered saline containing 
0.1% Tween 20 (TBS-T) and incubated with validated primary antibodies diluted in blocking buffer at room 
temperature for 1 h or at 4 °C overnight (Supplementary Table S3). Slides were washed with TBS-T and probed 
with secondary antibodies diluted in blocking buffer at room temperature for 30 min or 1 h. To amplify the 
signal, if applicable, slides were incubated with biotin and peroxidase blocking reagents (Dako) prior to primary 
antibody incubation and then with Bio-Rad Amplification Reagent (Bio-Rad) at room temperature for 15 min 
after secondary antibody incubation (Supplementary Table S2). Slides were washed with TBS-T. For staining 
Figure 4.  Integrative multi-platform RPPA analysis of drug-treated breast cancer cell lines. (a) Principal 
component analyses of integrated RPPA data of SKBR3 cells (top) or MDA-MB-231 cells (bottom) treated with 
lapatinib, selumetinib or vehicle control (DMSO) at two timepoints. (b) Volcano plots of RPPA data of SKBR3 
cells treated with lapatinib (top) or MDA-MB-231 cells treated with selumetinib (bottom) compared to those 
treated with vehicle control (DMSO) for 20 min. Differentially regulated phosphoproteins are labelled. Grey 
curves indicate 5% false discovery rate (n = 3 independent samples). (c) Integrated multi-platform RPPA data of 
drug-treated breast cancer cell lines were clustered on the basis of antibody-wise and sample-wise dissimilarities 
(Spearman rank correlation coefficient-based distance). Annotation bars indicate cell type, cell type receptor 
status, drug treatment and RPPA platform. (d) Clustered antibody antigen map for all antibodies used in the 
integrative analysis. The map is aligned with the hierarchical clustering results in c [grey dashed line above the 
left-most antibody indicates alignment of the first antibody (column) end-node] and coloured and ordered as 
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of total protein with SYPRO Ruby, slides were washed once with 7% acetic acid, 10% methanol (15 min), twice 
with deionised water, once with SYPRO Ruby (Thermo Fisher Scientific) and five times with deionised water. 
For staining of total protein with Fast Green FCF, slides were washed once with deionised water, once with 1% 
sodium hydroxide (15 min), twice with deionised water, once with 7% acetic acid, 30% methanol (15 min), once 
with 0.0025% Fast Green FCF (Sigma-Aldrich), 7% acetic acid, 30% methanol  (3 min), once with deionised 
water, once with 7% acetic acid, 30% methanol (15 min) and once with deionised water. Slides were allowed to 
dry at room temperature for 10 min prior to slide scanning. Slides were read using a GenePix 4000B (Molecular 
Devices), Odyssey (LI-COR Biosciences) or InnoScan 710-IR (Innopsys) scanner (Supplementary Table S2). The 
relative fluorescence intensity of each sample spot was quantified using MicroVigene (VigeneTech), GenePix Pro 
(Molecular Devices) or Mapix (Innopsys) software (Supplementary Table S2). For all platforms, signal intensities 
of < 1% of undiluted samples were below the lower limits of detection for all antibody antigens. Processed signal 
intensities were normalised using  NormaCurve16,  RPPanalyzer33,56 or spot-by-spot division of antibody signal 
intensity by total protein stain signal intensity (Supplementary Table S2).
Dataset integration. We used RPPA data derived from all three RPPA platforms that had been normalised 
using the respective in-house normalisation procedure of each platform (Supplementary Table S2). Normalised 
RPPA data derived from each platform were binary-logarithm transformed, unless they were so transformed as 
part of the platform-specific normalisation procedure, and stored as matrices of transformed normalised data 
points (elements) arranged in rows of different samples and columns of different antibodies. For data derived 
from each platform, for each column of the matrix representing data for an antibody, the median of all samples 
was calculated and this was subtracted from each element in that column. Matrices of antibody-wise median-
centred data derived from each platform were horizontally concatenated into a single matrix. Unique antibody 
identifiers were assigned to each distinct antibody based on antibody reference, and antibody antigens were clas-
sified to account for recognition of up to two related protein or phosphoprotein isoforms or family members (e.g. 
antibodies targeting Erk1 and Erk1/2 were classified as recognising Erk1/2) (Supplementary Table S3). Data for 
antibodies targeting the same antigen class used on all three RPPA platforms were used for dataset integration; 
antigen classes represented by data derived from fewer than three RPPA platforms were excluded from further 
analysis.
Unsupervised learning. Binary, agglomerative hierarchical cluster analyses of centred normalised abun-
dances for proteins and phosphoproteins were performed using Cluster 3.0 (C Clustering Library, version 
1.54)57. Spearman rank correlation coefficients, Euclidean distances and Kendall tau coefficients were calculated 
and adapted as distances, if necessary. Distance matrices were built using pairwise average linkage. Hierarchical 
clustering results were visualised using Java TreeView (version 1.1.5r2)58 and compiled using Illustrator (Adobe). 
Principal component analyses were performed using Python (version 3.7.4) or Perseus (version 1.5.2.6)59.
Clustered antibody antigen mapping. For data-driven representation of antibody similarity across 
multiple RPPA platforms, we devised the clustered antibody antigen map. For all antibodies used in the integra-
tive analysis, centred normalised abundances for proteins and phosphoproteins were clustered on the basis of 
Spearman rank correlation coefficient-based distance, Euclidean distance or Kendall tau coefficient-based dis-
tance using Cluster 3.0, computing distances with an average-linkage matrix. Clustered antibody (column) node 
memberships were stored for antibody mapping, and clustered antibodies were expanded in a second dimension 
according to antibody antigen classification. Antibodies targeting the same antigen class were indexed according 
to unique antibody identifier, enumerating from 1. A matrix of integer-indexed antibody identifier elements was 
generated according to clustered antibodies (columns) and corresponding antibody antigen classes (rows) (Sup-
plementary Table S3). In this matrix, antibody (column) node memberships determined by clustering of RPPA 
data were preserved, and antibody antigen classes (rows) were ordered alphabetically. The resulting clustered 
antibody–antigen feature space was used to annotate the integrated multi-platform RPPA data. Mapping results 
were visualised using Java TreeView and compiled using Illustrator.
Statistical analyses. No statistical methods were used to pre-determine sample size. Spearman rank cor-
relation coefficients were calculated for every pair-wise combination of antibody identifiers. Kernel density esti-
mates were computed using R (version 3.4.1)60. Median Spearman rank correlation coefficients were compared 
using Fisher transformation and two-sided z-tests. Differentially regulated proteins and phosphoproteins were 
compared using two-tailed Student’s t-tests with artificial within-groups variance set to 1 and a permutation-
based false discovery rate threshold of 5% (1,000 randomisations using Perseus).
Data availability
The datasets analysed during the current study are included in this published article (and its Supplementary 
Information files) or are available from the corresponding authors on reasonable request.
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